...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Another IPO that shocks!

narmac - The market doesn't have to make sense. RVX probably had a market cap of about $900 million back 15 years or so ago before they had a clue what they had. 35 million shares at $25 is $875 million. Yes, these companies have been badly mismanaged and the others might or might not do better. The market is tired of RVX and Zenith never fulfilling promises. Only they can change that.

Share
New Message
Please login to post a reply